Related Experiment Video

Updated: Apr 4, 2026

Fluorescence-based Monitoring of PAD4 Activity via a Pro-fluorescence Substrate Analog
08:37

Fluorescence-based Monitoring of PAD4 Activity via a Pro-fluorescence Substrate Analog

Published on: November 5, 2014

10.4K

OTUD4 Inhibits Prostate Cancer by Deubiquitinating MYH9

Zheng Qin1,2, Yueyao Zhang3, Dongze Liu4

  • 1Tianjin Key Laboratory of Precision Medicine for Sex Hormones and Diseases, The Second Hospital of Tianjin Medical University, Tianjin, 300211, China.

Oncology Research
|April 3, 2026
PubMed
Abstract

Insights

Ovarian tumor family deubiquitinase 4 (OTUD4) acts as a tumor suppressor in prostate cancer by preventing myosin-9 (MYH9) degradation. This discovery offers new therapeutic targets for improving prostate cancer prognosis.

Area of Science:

  • Oncology
  • Molecular Biology
  • Biochemistry

Background:

  • Prostate cancer is a leading cause of cancer death in men, necessitating novel therapeutic targets.
  • The role of Ovarian Tumor Family Deubiquitinase 4 (OTUD4) in prostate cancer pathogenesis is currently unknown.
  • Identifying new biological targets is critical for improving patient outcomes.

Purpose of the Study:

  • To investigate OTUD4 as a potential therapeutic target and diagnostic marker in prostate cancer.
  • To elucidate the underlying mechanisms of OTUD4's function in prostate cancer.

Main Methods:

  • Utilized cell culture, CCK-8, colony formation, Transwell, and EdU assays for in vitro analysis.
  • Employed immunofluorescence, Western blot, qRT-PCR, and protein mass spectrometry for molecular investigations.
  • Validated findings in vivo using nude mouse xenograft models and IHC/H&E staining.

Main Results:

  • OTUD4 expression was found to be downregulated in prostate cancer tissues and correlated with poorer prognosis.
  • OTUD4 was identified to directly inhibit the degradation of myosin-9 (MYH9) protein through deubiquitination.
  • Overexpression of MYH9 suppressed prostate cancer growth, suggesting a tumor-suppressive role mediated by cell adhesion molecules.

Conclusions:

  • OTUD4 functions as a tumor suppressor in prostate cancer.
  • OTUD4 stabilizes MYH9 protein levels via deubiquitination, thereby inhibiting prostate cancer progression.
  • The OTUD4-MYH9 axis represents a promising therapeutic strategy for prostate cancer.
Keywords:
Prostate cancermyosin-9 (MYH9)ovarian tumor family deubiquitinase 4 (OTUD4)therapeutic targetubiquitin (UB)

More Related Videos

MicroRNA Detection in Prostate Tumors by Quantitative Real-time PCR qPCR08:30

MicroRNA Detection in Prostate Tumors by Quantitative Real-time PCR qPCR

Published on: May 16, 2012

25.2K
miRNA Expression Analyses in Prostate Cancer Clinical Tissues11:29

miRNA Expression Analyses in Prostate Cancer Clinical Tissues

Published on: September 8, 2015

11.3K

Related Concept Videos

Abnormal Proliferation02:23

Abnormal Proliferation

Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the...
5.4K
Inhibition of Cdk Activity02:34

Inhibition of Cdk Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
6.2K
Inhibition of CDK Activity02:34

Inhibition of CDK Activity

5.7K
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
5.1K
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

1.7K
Induced Pluripotent Stem Cells01:06

Induced Pluripotent Stem Cells

Stem cells are undifferentiated cells that divide and produce different cell types. Ordinarily, cells that have differentiated into a specific cell type are terminally differentiated; however, scientists have found a way to reprogram these mature cells so that they dedifferentiate and return to an unspecialized, proliferative state. These cells are pluripotent like embryonic stem cells—able to produce all cell types—and are called induced pluripotent stem cells (iPSCs).
Somatic...
6.3K